Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV
(RTTNews) - Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses.